<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2023-3364</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-3364</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИНФАРКТ МИОКАРДА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MYOCARDIAL INFARCTION</subject></subj-group></article-categories><title-group><article-title>Биомаркеры воспаления и эндотелиальной дисфункции у пожилых пациентов с инфарктом миокарда, артериальной гипертензией и синдромом старческой астении</article-title><trans-title-group xml:lang="en"><trans-title>Biomarkers of inflammation and endothelial dysfunction in elderly patients with myocardial infarction, hypertension and frailty</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4821-3692</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Агарков</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Agarkov</surname><given-names>N. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Агарков Николай Михайлович — доктор медицинских наук, профессор кафедры биомедицинской инженерии, старший научный сотрудник лаборатории "Проблемы старения".</p><p>Курск; Белгород</p></bio><bio xml:lang="en"><p>Kursk; Belgorod</p></bio><email xlink:type="simple">vitalaxen@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6685-3183</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Охотников</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Okhotnikov</surname><given-names>O. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Охотников Олег Иванович — доктор медицинских наук, профессор кафедры лучевой диагностики и терапии.</p><p>Курск</p></bio><bio xml:lang="en"><p>Kursk</p></bio><email xlink:type="simple">kurskmed@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3978-8910</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Голиков</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Golikov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Голиков Альберт Витальевич — доктор медицинских наук, доцент кафедры хирургических болезней № 1.</p><p>Курск</p></bio><bio xml:lang="en"><p>Kursk</p></bio><email xlink:type="simple">kurskmed@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8074-3776</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Колпина</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kolpina</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Колпина Лола Владимировна — кандидат социологических наук, доцент кафедры социальных технологий.</p><p>Тель-Авив</p></bio><bio xml:lang="en"><p>Tel Aviv</p></bio><email xlink:type="simple">kolpina@bsu.edu.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8074-3776</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коломиец</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kolomiets</surname><given-names>V. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Заочный аспирант.</p><p>Курск</p></bio><bio xml:lang="en"><p>Kursk</p></bio><email xlink:type="simple">kurskmed@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Юго-Западный государственный университет; Белгородский государственный национальный исследовательский университет</institution></aff><aff xml:lang="en"><institution>Southwest State University; Belgorod National Research University</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Курский государственный медицинский университет Минздрава России</institution></aff><aff xml:lang="en"><institution>Kursk State Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Тель-Авивский университет</institution></aff><aff xml:lang="en"><institution>Tel Aviv University</institution></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Юго-Западный государственный университет</institution></aff><aff xml:lang="en"><institution>Southwest State University</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>11</day><month>04</month><year>2023</year></pub-date><volume>22</volume><issue>3</issue><fpage>3364</fpage><lpage>3364</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Агарков Н.М., Охотников О.И., Голиков А.В., Колпина Л.В., Коломиец В.И., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Агарков Н.М., Охотников О.И., Голиков А.В., Колпина Л.В., Коломиец В.И.</copyright-holder><copyright-holder xml:lang="en">Agarkov N.M., Okhotnikov O.I., Golikov A.V., Kolpina L.V., Kolomiets V.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/3364">https://cardiovascular.elpub.ru/jour/article/view/3364</self-uri><abstract><sec><title>Цель</title><p>Цель. Анализ уровня биомаркеров воспаления и эндотелиальной дисфункции у пожилых пациентов с инфарктом миокарда (ИМ), артериальной гипертензией (АГ) и синдромом старческой астении (ССА).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Сформировано три клинические группы: пациенты 60-74 лет с ИМ+АГ 1-2 ст. (n=80); пациенты 60-74 лет с ИМ+АГ+преастения (ПА) (n=52); пациенты 60-74 лет с ИМ+АГ+ССА (n=114). У пациентов всех групп через 2-4 мес. после ИМ определялись уровни высокочувствительного С-реактивного белка (вчСРБ), молекул межклеточной адгезии (ICAM-1), метаболитов оксида азота (NO) — нитратов и нитритов, эндотелина-1, десквамированных эндотелиоцитов, фактора роста роста эндотелия сосудов (VEGF).</p></sec><sec><title>Результаты</title><p>Результаты. У пациентов с ИМ+АГ+ССА установлено более высокое содержание в крови вчСРБ — 6,4 мг/л по сравнению с пациентами с ИМ+АГ+ПА (4,2 мг/л; p&lt;0,01) и с пациентами с ИМ+АГ (3,2 мг/л; p&lt;0,01). Уровень другого биомаркера воспаления ICAM-1 составил в указанных группах 315,6, 242,7 и 213,5 нг/мл, соответственно (р&lt;0,01). У пациентов с ИМ+АГ+ПА диагностированы низкие уровни нитрита (NO2-) и нитрата (NO3-) — 6,7 и 5,4 мкмоль/л у пациентов с ИМ+АГ+ССА vs 7,2 мкмоль/л у пациентов с ИМ+АГ (p&lt;0,01). Аналогичное соотношение присуще нитрату NO3-. Напротив, содержание десквамированных эндотелиоцитов и VEGF было статистически значимо выше у пациентов с ИМ+АГ+ССА по сравнению с пациентами с ИМ+АГ+ПА (р&lt;0,01). Существенно выше у пациентов с ИМ+АГ+ССА по сравнению с группой ИМ+АГ+ПА оказался и уровень эндотелина-1: 18,85 vs 13,41 фмоль/л в (p&lt;0,05). Заключение. Уровни показателей воспаления и эндотелиальной дисфункции у пациентов с ИМ+АГ статистически значимо превышают таковые у пациентов с ИМ+АГ+ССА по сравнению с пациентами с ИМ+АГ+ПА и с ИМ+АГ, за исключением метаболитов оксида азота.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To analyze the level of biomarkers of inflammation and endothelial dysfunction in elderly patients with myocardial infarction (MI), hypertension (HTN) and frailty.</p></sec><sec><title>Material and methods</title><p>Material and methods. Three following clinical groups were formed: patients aged 60-74 years with MI+ grade 1-2 HTN (n=80); patients aged 60-74 with MI+HTN+prefrailty (n=52); patients aged 60-74 years with MI+HTN+frailty (n=114). In patients of all groups 2-4 months after MI, the levels of high-sensitivity C-reactive protein (hsCRP), intercellular adhesion molecule 1 (ICAM-1), nitric oxide (NO) metabolites — nitrates and nitrites, endothelin-1, desquamated endotheliocytes, vascular endothelial growth factor (VEGF) were determined.</p></sec><sec><title>Results</title><p>Results. Patients with MI+HTN+frailty had a higher hsCRP — 6,4 mg/l compared with patients with MI+HTN+ prefrailty (4,2 mg/l; p&lt;0,01) and patients with MI+HTN (3,2 mg/l; p&lt;0,01). The level of ICAM-1 was 315,6, 242,7, and 213,5 ng/ml, respectively, in these groups (p&lt;0,01). Patients with MI+HTN+prefrailty, MI+HTN+frailty and MI+HTN had following levels of nitrite (NO2-) and nitrate (NO3-) — 6,7, 5,4, and 7,2 pmol/l (p&lt;0,01). A similar ratio is inherent in NO3-. On the contrary, the content of desquamated endotheliocytes and VEGF was significantly higher in patients with MI+HTN+frailty compared with patients with MI+HTN+ prefrailty (p&lt;0,01). The level of endothelin-1 was also significantly higher in patients with MI+HTN+frailty compared with the MI+HTN+prefrailty group: 18,85 vs 13,41 fmol/l (p&lt;0,05).</p></sec><sec><title>Conclusion</title><p>Conclusion. The levels of inflammation and endothelial dysfunction in patients with MI+HTN are significantly higher than those in patients with MI+HTN+frailty compared with patients with MI+AH+prefrailty and MI+HTN, with the exception of nitric oxide metabolites.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>инфаркт миокарда</kwd><kwd>артериальная гипертензия</kwd><kwd>синдром старческой астении</kwd><kwd>маркеры воспаления</kwd><kwd>эндотелиальная дисфункция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>myocardial infarction</kwd><kwd>hypertension</kwd><kwd>frailty</kwd><kwd>inflammatory markers</kwd><kwd>endothelial dysfunction</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Гарганеева А. А., Округин С. А., Борель К.Н. и др. Инфаркт миокарда на рубеже двух столетий: демографические и социальные тенденции. Клиническая медицина. 2016;94(6):463-6. doi:10.18821/0023-2149-2016-94-6-463-466.</mixed-citation><mixed-citation xml:lang="en">Garganeeva AA, Okrugin SA, Borel KN, et al. Myocardial infarction at the turn of two centuries: demographic and social trends. Clinical medicine. 2016;94(6):463-6. (In Russ.) doi:10.18821/0023-2149-2016-94-6-463-466.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Лавринова Е. А., Брылякова Д. Н., Кухарчик Г. А. Влияние синдрома старческой астении на течение острого коронарного синдрома без подъема сегмента ST и исходы у пациентов пожилого и старческого возраста. Скорая медицинская помощь. 2020;21(2):48-54. doi:10.24884/2072-6716-2020-21-2-48-54.</mixed-citation><mixed-citation xml:lang="en">Lavrinova EA, Brylyakova DN, Kukharchik GA. The effect of senile asthenia syndrome on the course of acute coronary syndrome without ST segment elevation and outcomes in elderly and senile patients. Emergency medical care. 2020;21(2):48-54. (In Russ.) doi:10.24884/2072-6716-2020-21-2-48-54.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Лутай Ю. А. Рассогласование суточных биоритмов артериального давления и частоты сердечных сокращений у пожилых больных инфарктом миокарда. Научные результаты биомедицинских исследований. 2021;7(1):80-5. doi:10.18413/2658-6533-2020-7-1-0-8.</mixed-citation><mixed-citation xml:lang="en">Lutai YA. Mismatch of daily biorhythms of blood pressure and heart rate in elderly patients with myocardial infarction. Research Results in Biomedicine. 2021;7(1):80-5. (In Russ.) doi:10.18413/2658-6533-2020-7-1-0-8.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ткачёва О. Н., Котовская Ю. В., Феоктистова К. В. и др. Острый коронарный синдром в старческом возрасте: проблемы и нерешенные вопросы. Кардиоваскулярная терапия и профилактика. 2017;16(3):62-7. doi:10.15829/1728-8800-2017-3-62-67.</mixed-citation><mixed-citation xml:lang="en">Tkacheva ON, Kotovskaya YuV, Feoktistova KV, et al. Acute coronary syndrome in old age: problems and unresolved issues. Cardiovascular Therapy and Prevention. 2017;16(3):62-7. (In Russ.) doi:10.15829/1728-8800-2017-3-62-67.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Соселия Н. Н., Багманова Н. Х., Виллевальде С. В. и др. Проявления синдрома старческой астении у пациентов старческого возраста и долгожителей с острым коронарным синдромом. Вестник российского университета дружбы народов. 2018;22(2):141-7. doi:10.22363/2313-0245-2018-22-2-141-147.</mixed-citation><mixed-citation xml:lang="en">Soselia NN, Bagmanova NH, Villevalde SV, et al. Manifestations of senile asthenia syndrome in senile patients and centenarians with acute coronary syndrome. Bulletin of the Peoples' Friendship University of Russia. 2018;22(2):141-7. (In Russ.) doi:10.22363/2313-0245-2018-22-2-141-147.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Tonet E, Pavasini R, Biscaglia S, et al. Frailty in patients admitted to hospital for acute coronary syndrome: when, how and why? Journal of geriatric cardiology. 2019;16(2):129-37. doi:10.11909/j.issn.1671-5411.2019.02.005.</mixed-citation><mixed-citation xml:lang="en">Tonet E, Pavasini R, Biscaglia S, et al. Frailty in patients admitted to hospital for acute coronary syndrome: when, how and why? Journal of geriatric cardiology. 2019;16(2):129-37. doi:10.11909/j.issn.1671-5411.2019.02.005.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Velissaris D, Pantzaris N, Koniari I, et al. C-Reactive Protein and Frailty in the Elderly: A Literature Review. J Clin Med Res. 2017;9(6):461-5. doi:10.14740/jocmr2959w.</mixed-citation><mixed-citation xml:lang="en">Velissaris D, Pantzaris N, Koniari I, et al. C-Reactive Protein and Frailty in the Elderly: A Literature Review. J Clin Med Res. 2017;9(6):461-5. doi:10.14740/jocmr2959w.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Yao SM, Zheng PP, Wan YH, et al. Adding high-sensitivity C-reactive protein to frailty assessment to predict mortality and cardiovascular events in elderly inpatients with cardiovascular disease. Exp Gerontol. 2021;146:111235. doi:10.1016/j.exger.2021.111235.</mixed-citation><mixed-citation xml:lang="en">Yao SM, Zheng PP, Wan YH, et al. Adding high-sensitivity C-reactive protein to frailty assessment to predict mortality and cardiovascular events in elderly inpatients with cardiovascular disease. Exp Gerontol. 2021;146:111235. doi:10.1016/j.exger.2021.111235.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Lee WJ, Chen LK, Liang CK, et al. Soluble ICAM-1, Independent of IL-6, Is Associated with Prevalent Frailty in Community-Dwelling Elderly Taiwanese People. PLoS One. 2016;11(6):e0157877. doi:10.1371/journal.pone.0157877.</mixed-citation><mixed-citation xml:lang="en">Lee WJ, Chen LK, Liang CK, et al. Soluble ICAM-1, Independent of IL-6, Is Associated with Prevalent Frailty in Community-Dwelling Elderly Taiwanese People. PLoS One. 2016;11(6):e0157877. doi:10.1371/journal.pone.0157877.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Alonso-Bouzon C, Carcaillon L, Garcia-Garcia FJ, et al. Association between endothelial dysfunction and frailty: the Toledo Study for Healthy Aging. Age (Dordr). 2014;36(1):495-505. doi:10.1007/s11357-013-9576-1.</mixed-citation><mixed-citation xml:lang="en">Alonso-Bouzon C, Carcaillon L, Garcia-Garcia FJ, et al. Association between endothelial dysfunction and frailty: the Toledo Study for Healthy Aging. Age (Dordr). 2014;36(1):495-505. doi:10.1007/s11357-013-9576-1.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Roumeliotis S, Veljkovic A, Georgianos PI, et al. Association between Biomarkers of Oxidative Stress and Inflammation with Cardiac Necrosis and Heart Failure in Non-ST Segment Elevation Myocardial Infarction Patients and Various Degrees of Kidney Function. Oxid Med Cell Longev. 2021;2021:3090120. doi:10.1155/2021/3090120.</mixed-citation><mixed-citation xml:lang="en">Roumeliotis S, Veljkovic A, Georgianos PI, et al. Association between Biomarkers of Oxidative Stress and Inflammation with Cardiac Necrosis and Heart Failure in Non-ST Segment Elevation Myocardial Infarction Patients and Various Degrees of Kidney Function. Oxid Med Cell Longev. 2021;2021:3090120. doi:10.1155/2021/3090120.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y, Shao T, Yao L, et al. Effects of tirofiban on stent thrombosis, Hs-CRP, IL-6 and sICAM-1 after PCI of acute myocardial infarction. Exp Ther Med. 2018;16(4):3383-8. doi:10.3892/etm.2018.6589.</mixed-citation><mixed-citation xml:lang="en">Zhang Y, Shao T, Yao L, et al. Effects of tirofiban on stent thrombosis, Hs-CRP, IL-6 and sICAM-1 after PCI of acute myocardial infarction. Exp Ther Med. 2018;16(4):3383-8. doi:10.3892/etm.2018.6589.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Прудников А. Р. Оценка риска развития острого коронарного синдрома на основе исследования профиля цитокинов и протеолитической активности сыворотки крови. Иммунопатология, аллергология, инфектология. 2019;1:25-33. doi:10.14427/jipai.2019.1.25.</mixed-citation><mixed-citation xml:lang="en">Prudnikov AR. Risk assessment of acute coronary syndrome based on the study of cytokine profile and proteolytic activity of blood serum. Immunopathology, allergology, infectology. 2019;1:25-33. (In Russ.) doi:10.14427/jipai.2019.1.25.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Roffie M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. doi:10.1093/eurheartj/ehv320.</mixed-citation><mixed-citation xml:lang="en">Roffie M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. doi:10.1093/eurheartj/ehv320.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Жернакова Ю. В. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31. doi:10.26442/2075082X.2019.1.190179.</mixed-citation><mixed-citation xml:lang="en">Chazova IE, Zhernakova YuV. Clinical recommendations. Diagnosis and treatment of arterial hypertension. Systemic hypertension. 2019;16(1):6-31. (In Russ) doi:10.26442/2075082X.2019.1.190179.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J. Geront. Med. Sci. 2001;56(3):146-56. doi:10.1093/gerona/56.3.m146.</mixed-citation><mixed-citation xml:lang="en">Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J. Geront. Med. Sci. 2001;56(3):146-56. doi:10.1093/gerona/56.3.m146.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao L, Li Y, Xu T, et al. Impact of increased inflammation biomarkers on periprocedural myocardial infarction in patients undergoing elective percutaneous coronary intervention: a cohort study. J Thorac Dis. 2020;12(10):5398-410. doi:10.21037/jtd-20-1605.</mixed-citation><mixed-citation xml:lang="en">Zhao L, Li Y, Xu T, et al. Impact of increased inflammation biomarkers on periprocedural myocardial infarction in patients undergoing elective percutaneous coronary intervention: a cohort study. J Thorac Dis. 2020;12(10):5398-410. doi:10.21037/jtd-20-1605.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ries W, Torzewski J, Heigl F, et al. C-Reactive Protein Aphe-resis as Anti-inflammatory Therapy in Acute Myocardial Infarction: Results of the CAMI-1 Study. Front Cardiovasc Med. 2021;8:591714. doi:10.3389/fcvm.2021.591714.</mixed-citation><mixed-citation xml:lang="en">Ries W, Torzewski J, Heigl F, et al. C-Reactive Protein Aphe-resis as Anti-inflammatory Therapy in Acute Myocardial Infarction: Results of the CAMI-1 Study. Front Cardiovasc Med. 2021;8:591714. doi:10.3389/fcvm.2021.591714.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">McKechnie DG, Papacosta AO, Lennon LT, et al. Associations between inflammation, cardiovascular biomarkers and incident frailty: the British Regional Heart Study. Age Ageing. 2021;50(6):1979-87. doi:10.1093/ageing/afab143.</mixed-citation><mixed-citation xml:lang="en">McKechnie DG, Papacosta AO, Lennon LT, et al. Associations between inflammation, cardiovascular biomarkers and incident frailty: the British Regional Heart Study. Age Ageing. 2021;50(6):1979-87. doi:10.1093/ageing/afab143.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Stewart R. Cardiovascular Disease and Frailty: What Are the Mechanistic Links? Clin Chem. 2019;65(1):80-6. doi:10.1373/ clinchem.2018.287318.</mixed-citation><mixed-citation xml:lang="en">Stewart R. Cardiovascular Disease and Frailty: What Are the Mechanistic Links? Clin Chem. 2019;65(1):80-6. doi:10.1373/ clinchem.2018.287318.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Liu ZY, Wang ZD, Li LZ, et al. Association of CRP gene polymorphisms with CRP levels, frailty and co-morbidity in an elderly Chinese population: results from RuLAS. Age Ageing. 2016;45(3):360-5. doi:10.1093/ageing/afw041.</mixed-citation><mixed-citation xml:lang="en">Liu ZY, Wang ZD, Li LZ, et al. Association of CRP gene polymorphisms with CRP levels, frailty and co-morbidity in an elderly Chinese population: results from RuLAS. Age Ageing. 2016;45(3):360-5. doi:10.1093/ageing/afw041.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hwang AC, Liu LK, Lee WJ, et al. Association of Frailty and Cardiometabolic Risk Among Community-Dwelling MiddleAged and Older People: Results from the I-Lan Longitudinal Aging Study. Rejuvenation Res. 2015;18(6):564-72. doi:10.1089/rej.2015.1699.</mixed-citation><mixed-citation xml:lang="en">Hwang AC, Liu LK, Lee WJ, et al. Association of Frailty and Cardiometabolic Risk Among Community-Dwelling MiddleAged and Older People: Results from the I-Lan Longitudinal Aging Study. Rejuvenation Res. 2015;18(6):564-72. doi:10.1089/rej.2015.1699.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Veronese N, Cereda E, Stubbs B, et al. Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. Ageing Res Rev. 2017;35:63-73. doi:10.1016/j.arr.2017.01.003.</mixed-citation><mixed-citation xml:lang="en">Veronese N, Cereda E, Stubbs B, et al. Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. Ageing Res Rev. 2017;35:63-73. doi:10.1016/j.arr.2017.01.003.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Liang YD, Liu Q, Du MH, et al. Urinary 8-oxo-7,8-dihydroguanosine as a potential biomarker of frailty for elderly patients with cardiovascular disease. Free Radic Biol Med. 2020;152:248-54. doi:10.1016/j.freeradbiomed.2020.03.011.</mixed-citation><mixed-citation xml:lang="en">Liang YD, Liu Q, Du MH, et al. Urinary 8-oxo-7,8-dihydroguanosine as a potential biomarker of frailty for elderly patients with cardiovascular disease. Free Radic Biol Med. 2020;152:248-54. doi:10.1016/j.freeradbiomed.2020.03.011.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Assar ME, Angulo J, Vallejo S, et al. Mechanisms involved in the aging-induced vascular dysfunction. Front Physiol. 2012;3:132. doi:10.3389/fphys.2012.00132.</mixed-citation><mixed-citation xml:lang="en">Assar ME, Angulo J, Vallejo S, et al. Mechanisms involved in the aging-induced vascular dysfunction. Front Physiol. 2012;3:132. doi:10.3389/fphys.2012.00132.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Stuhlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation. 2003;108(8):933-8. doi:10.1161/01.CIR.0000085067.55901.89.</mixed-citation><mixed-citation xml:lang="en">Stuhlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation. 2003;108(8):933-8. doi:10.1161/01.CIR.0000085067.55901.89.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Подзолков В. И., Брагина А. Е., Дружинина Н. А. Прогностическая значимость маркеров эндотелиальной дисфункции у больных гипертонической болезнью. Российский кардиологический журнал. 2018;(4):7-13. doi:10.15829/1560-4071-2018-4-7-13.</mixed-citation><mixed-citation xml:lang="en">Podzolkov VI, Bragina AE, Druzhinina NA. Prognostic significance of markers of endothelial dysfunction in patients with hypertension. Russian Journal of Cardiology. 2018;(4):7-13. (In Russ.) doi:10.15829/1560-4071-2018-4-7-13.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Чукаева И.И., Спирякина Я.Г., Орлова Н.В. и др. Оценка маркёров воспаления и эндотелиальной дисфункции у пациентов с артериальной гипертензией на фоне достижения целевого уровня артериального давления. Клиническая лабораторная диагностика. 2018;63(6):337-40.</mixed-citation><mixed-citation xml:lang="en">Chukaeva II, Spiryakina YaG, Orlova NV, et al. Evaluation of markers of inflammation and endothelial dysfunction in patients with arterial hypertension against the background of achieving the target blood pressure level. Clinical laboratory diagnostics. 2018;63(6):337-40. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Фуштей И. М., Голдовский Б. М., Мочёный В. О. и др. Современные представления о механизмах поражения сосудов при гипертонической болезни и атеросклерозе. Медицина неотложных состояний. 2015;69(6):26-29.</mixed-citation><mixed-citation xml:lang="en">Fushtei IM, Goldovsky BM, Mocheny VO, et al. Modern ideas about the mechanisms of vascular damage in hypertension and atherosclerosis. Emergency medicine. 2015;69(6):26-9. (In Russ.)</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
